Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

This was the stock's third consecutive day of losses.

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

This was the stock's second consecutive day of losses.

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%.

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...